Clinical Trial Search

Primary: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in…

Primary: Simple Appetite Questionnaire — 8.7; 9.57; 11.26; 9.93 score on a scale

Primary: Limbal Redness - DDSH, DDH, Non-lens Groups — 0.41; 0.37; 0.44; 0.49 score on a scale

Primary: Change in Intentions to be Screened for Colorectal Cancer. — 2.5 score on a scale — p=<0.001

Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years — 80300; 62900…

Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD) — 48.1; 35.5 score on a scale

Primary: The Correlation Between the Paired BIS Value Categories and Clinical Sedation Scores — 0.917; 0.874 correlation coefficient

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: VIO System Imaging Performance — 122 # participants with acceptable images

Primary: Change in Blood Volume — -320; -447 mL — p=0.56

Primary: Change in the Percentage of Fat Thickness From Baseline to 12-weeks Post-treatment — -6.9 percentage of body fat

Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303

Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants

Primary: Midline Localization — 0.9 mm

Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004